HomeNewsBusinessAfter early boom, fintech lending startups face a reality check

After early boom, fintech lending startups face a reality check

The difficulty borrowers face in repaying their loans is forcing many fintech lending startups to restructure loans and show them as ‘standard assets’ as the year draws to a close.

Bengaluru / December 24, 2020 / 17:38 IST
Story continues below Advertisement
For large-value MSME loans, recovery and collections could both be a challenge.
For large-value MSME loans, recovery and collections could both be a challenge.

Fintech lending startups were one of the biggest beneficiaries of the COVID-19 pandemic as business boomed when people facing business distress or coping with a job loss scrambled for loans. Now, as the year draws to a close, these lenders are the ones in distress, scrambling to offer those same customers restructured options as defaults rise.

The lending startups have also come under scrutiny due to alleged harassment of borrowers, which has resulted in deaths. On December 23, the Reserve Bank of India (RBI) took note of the unbridled growth of these platforms.

Story continues below Advertisement

Platforms that cater to organised and salaried customers are still better off, but lenders processing business loans are facing trouble collecting repayments from enterprises that bore the brunt of the pandemic.

Though overall industry numbers are not out yet, people who track the segment said repayments for business loans are likely lagging at 50-60 percent. Repayments for consumer loans are back at 90 percent and sometimes more, they said, requesting anonymity. 

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show